Authors: | Yang, X.; Sen, F.; Geyer, M. B. |
Article Title: | Inotuzumab ozogamicin as chemotherapy-sparing salvage in a 67-year-old man with primary refractory B-cell acute lymphoblastic leukemia with high-risk genomic features |
Abstract: | Older adults with acute lymphoblastic leukemia (ALL) continue to have a poor prognosis, in part due to greater chemotherapy-related toxicities. We herein report a 67-year-old man with Philadelphia chromosome (Ph)-negative B-cell ALL, who exhibited refractoriness to 3 different regimens of induction chemotherapy and experienced multiple complications including intracranial bleeding and respiratory failure, who achieved minimal residual disease (MRD)-negative complete response (CR) after a single cycle of inotuzumab ozogamicin (IO). His ALL was characterized by several high-risk mutations, which may have contributed to chemotherapy-refractory disease. Our case supports incorporating IO into front-line induction regimens for older adults with high-risk B-cell ALL. © 2019 |
Keywords: | clinical article; aged; primary tumor; gene mutation; case report; cancer risk; antineoplastic agent; cancer immunotherapy; acute lymphoblastic leukemia; high risk patient; cancer resistance; immunotherapy; genetic risk; brain hemorrhage; induction chemotherapy; respiratory failure; b cell leukemia; inotuzumab ozogamicin; philadelphia chromosome negative cell; older adults; human; male; priority journal; article |
Journal Title: | Leukemia Research Reports |
Volume: | 12 |
ISSN: | 2213-0489 |
Publisher: | Elsevier Inc. |
Date Published: | 2019-01-01 |
Start Page: | 100186 |
Language: | English |
DOI: | 10.1016/j.lrr.2019.100186 |
PROVIDER: | scopus |
PMCID: | PMC6904788 |
PUBMED: | 31867204 |
DOI/URL: | |
Notes: | Article -- Source: Scopus |